Novo says its next-gen obesity drug tops Lilly rival in late-stage study
6 Articles
6 Articles
CagriSema, a new generation pen still undergoing clinical trials, provided a higher average weight loss than the Mounjaro. The announcement was made on Monday by Danish pharmacist Novo Nordisk, a manufacturer of medicines such as Ozempic and Wegovy, who is leading the development of CagriSema, according to information from Reuters. Why is intestinal cancer increasing among young people? Understand what changes: Jehovah's Witnesses flexibility ru…
Novo says CagriSema tops Lilly rival in diabetes patients for weight loss - Regional Media News
Sept 21 (Reuters) - Novo Nordisk said on Monday its next-generation experimental drug, CagriSema, delivered an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes, outperforming Eli Lilly's rival drug. It has been seen as a successor to Novo's weight [...]
Novo says its next-gen obesity drug tops Lilly rival in late-stage study
Sept 21 (Reuters) - Novo Nordisk said on Monday its next-generation experimental drug had achieved an estimated average weight loss of 12.4% in a late-stage trial and that it was superior to Eli Lilly's drug. (Reporting by Sriparna ...
Novo Nordisk's experimental drug CagriSema led to an average weight loss of 12.4% in a late-stage clinical trial in diabetic patients. In this regimen, it outperformed tirzepatide, a compound used in Eli Lilly's Mounjaro and Zepbound drugs. However, the comparison involved specific, relatively low doses of both drugs.
Coverage Details
Bias Distribution
- 75% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
